This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (55)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Medical Ethics  • Statistics and Research Methods  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Humanities  • Medicine and the Media  • Alert me on articles by topic  Social Bookmarking   What's this?

The Adverse Effects of Industry Influence

Catherine D. DeAngelis, MD, MPH; Phil B. Fontanarosa, MD, MBA

JAMA. 2008;299(15):1833-1835.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The profession of medicine, in every aspect—clinical, education, and research—has been inundated with profound influence from the pharmaceutical and medical device industries. This has occurred because physicians have allowed it to happen, and it is time to stop.

Two articles^1-2 in this issue of JAMA provide a glimpse of one company's apparent misrepresentation of research data and its manipulation of clinical research articles and clinical reviews; such information and articles influence the education and clinical practice of physicians and other health professionals. The direct influence of for-profit companies on education^3-6 and clinical practice^7-8 has been well documented, so this Editorial deals primarily with clinical research.

The articles by Ross and colleagues¹ and by Psaty and Kronmal² document how one company, Merck & Co Inc, apparently manipulated dozens of publications to promote one of its products. But make no mistake—the manipulation . . . [Full Text of this Article]

Author Affiliations: Dr DeAngelis is Editor in Chief (cathy.deangelis@jama-archives.org) and Dr Fontanarosa is Executive Deputy Editor, JAMA.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Kent R. Johnson and Marissa N. D. Lassere
JAMA. 2008;300(8):900.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Steven Ferris, Douglas Galasko, and Louis Kirby
JAMA. 2008;300(8):901-902.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Richard Balon
JAMA. 2008;300(8):902.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Hervé Maisonneuve
JAMA. 2008;300(8):903.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Hean T. Ong and Jin S. Cheah
JAMA. 2008;300(8):903-904.
EXTRACT | FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Peter A. Lachenbruch and Ronald Wasserstein
JAMA. 2008;300(8):904.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
Joseph S. Ross, Kevin P. Hill, David S. Egilman, and Harlan M. Krumholz
JAMA. 2008;299(15):1800-1812.
ABSTRACT | FULL TEXT  

Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation
Bruce M. Psaty and Richard A. Kronmal
JAMA. 2008;299(15):1813-1817.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ethical Issues in Cardiovascular Research Involving Humans
Frye et al.
Circulation 2009;120:2113-2121.
FULL TEXT  

Physicians, the industry and population health
Gervas and Mansfield
J. Epidemiol. Community Health 2009;63:773-774.
FULL TEXT  

Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Hietanen
Ann Oncol 2009;20:1749-1751.
FULL TEXT  

A Time to Raise Our Voice(s)
Park and Swanstrom
SURG INNOV 2009;16:205-206.
 

Bidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?
Lanier
Mayo Clin Proc. 2009;84:771-775.
FULL TEXT  

Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals
Hirsch
Mayo Clin Proc. 2009;84:811-821.
FULL TEXT  

Americans' Attitudes Toward Psychiatric Medications: 1998-2006
Mojtabai
Psychiatr. Serv. 2009;60:1015-1023.
ABSTRACT | FULL TEXT  

The Need for Improved Access to FDA Reviews
O'Connor
JAMA 2009;302:191-193.
FULL TEXT  

Resolving Unreported Conflicts of Interest
DeAngelis and Fontanarosa
JAMA 2009;302:198-199.
FULL TEXT  

The Role of Conflict of Interest in Reporting of Scientific Information
Irwin
Chest 2009;136:253-259.
ABSTRACT | FULL TEXT  

Time for the Medical Profession to Act: New Policies Needed Now on Interactions Between Pharmaceutical Companies and Physicians
Greenland
Arch Intern Med 2009;169:829-831.
FULL TEXT  

Publication Bias and the Efficacy of Antidepressants
Mathew and Charney
Am. J. Psychiatry 2009;166:140-145.
FULL TEXT  

Why Guideline-Making Requires Reform
Sniderman and Furberg
JAMA 2009;301:429-431.
FULL TEXT  

The Neurontin Legacy -- Marketing through Misinformation and Manipulation
Landefeld and Steinman
NEJM 2009;360:103-106.
FULL TEXT  

News Media Coverage of Medication Research: Reporting Pharmaceutical Company Funding and Use of Generic Medication Names
Hochman et al.
JAMA 2008;300:1544-1550.
ABSTRACT | FULL TEXT  

Industry-Sponsored Negative Trials and the Potential Pitfalls of Post Hoc Analysis
Tribble
Arch Surg 2008;143:933-934.
FULL TEXT  

Industry-Sponsored Clinical Research: A Broken System
Angell
JAMA 2008;300:1069-1071.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Johnson and Lassere
JAMA 2008;300:900-900.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Balon
JAMA 2008;300:902-902.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Maisonneuve
JAMA 2008;300:903-903.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Lachenbruch and Wasserstein
JAMA 2008;300:904-904.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Ferris et al.
JAMA 2008;300:901-902.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
Ong and Cheah
JAMA 2008;300:903-904.
FULL TEXT  

Should the drug industry work with key opinion leaders? Yes
Buckwell
BMJ 2008;336:1404-1404.
FULL TEXT  

Who is an author?
Swedberg
Eur J Heart Fail 2008;10:523-524.
FULL TEXT